Form 4: Gossamer Bio CEO Granted 1,540,000 Stock Options

Faheem Hasnain, President & CEO of Gossamer Bio, Inc., was granted 1,540,000 stock options on March 4, 2025, according to a Form 4 filing.

Summary

• Faheem Hasnain, the President & CEO of Gossamer Bio, Inc., received 1,540,000 stock options on March 4, 2025.
• The exercise price of these options is $1.13.
• The options vest over time, with 25% vesting on March 4, 2026, and the remaining 75% vesting monthly over the subsequent 36 months, contingent upon continuous service to the Issuer.
• The options expire on March 3, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The vesting schedule is a positive sign for long-term commitment.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and vesting schedule of the grant are typical considerations.

Comparison to Industry Standards

• Stock option grants to CEOs in the biotech industry vary widely depending on company size, stage of development, and performance.
• Comparing this grant to similar companies like Arcus Biosciences or Revolution Medicines would require analyzing their executive compensation packages and stock ownership guidelines.
• Generally, vesting schedules that extend over several years are standard practice to ensure long-term alignment.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to increase company value.
• Employees may see this as a sign of confidence in the company's future.

Key Dates